source
- Erasca releases early-stage RAS drug data amid legal dispute with Revolution MedicinesErasca has released early-stage data on its RAS-targeting compound, doing so after receiving a legal threat from rival Revolution Medicines. Revolution recently announced a new drug that revived h…
- Thermo Fisher to divest microbiology unit to Astorg for $1.075 billion; Ligand announces purchase of XOMAThermo Fisher Scientific announced it will sell its microbiology business, part of its specialty diagnostics segment, to European private‑equity firm Astorg. The transaction is valued at $1.075 bi…